- Centers & Specialties
- Clinical Interests
- Non-Hodgkin's lymphoma (NHL)
- Hodgkin's lymphoma (also known as Hodgkin's disease)
- Chronic lymphocytic leukemia (CLL)
- HIV / AIDS-associated lymphoma
- Post-transplant lymphoproliferative diseases (PTLD)
- Medical Education
- MD, Mount Sinai School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital|Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Patient Gateway
- Yes, learn more
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Assistant Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology and Hematology.
Dr. Abramson's clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas (both B-cell and T-cell lymphomas), as well as Hodgkin lymphoma (also called Hodgkin's Disease), and Chronic Lymphocytic Leukemia (CLL). His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials of new cancer therapies in these diseases. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and a Fellow of the American College of Physicians. Dr. Abramson is the author of numerous papers and book chapters on lymphoma, and lectures widely.
- Research Summary
- Dr. Abramson designs and conducts clinical trials of novel therapies for the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia (CLL).
Abramson JS and Shipp MA. Advances in the biology, natural history and therapy of diffuse large B-cell lymphoma. Blood 2005.
Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis and management. Oncologist 2006.
Abramson JS, Chatterji M et al. A 51-year-old woman with splenomegaly and anemia. N Engl J Med 2008.
Abramson JS, Chen W, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haem 2009.
Abramson JS. Approach to the Patient with Lymphoma. In: Goroll AH and Mulley AG, editors. Primary Care Medicine 6th ed. LW&W 2009.
Abramson JS, Digumarthy S et al. A 56-Year-Old Woman with Fever, Rash, and Lymphadenopathy. N Engl J Med 2009.
Abramson JS and Scadden DT. Neoplasms in Acquired Immunodeficiency Syndrome. In: Kufe DW, et al. editors. Cancer Medicine 8. BC Decker 2010.
Canellos GP, Abramson JS et al. Treatment of favorable, limited-stage Hodgkins lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010.
Abramson JS, Hellmann M et al. Intravenous Methotrexate as CNS prophylaxis is associated with a low risk of CNS recurrence in high risk patients with Diffuse Large B Cell Lymphoma. Cancer 2010.
Barnes JA... and Abramson JS. Evaluation of the addition of Ritiximab to CODOX-M/IVAC for Burkitt's Lymphoma. Ann Oncol 2011.
Barnes JA... and Abramson JS. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin lymphoma. Ann Oncol 2011.
Zelenetz AD, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkins lymphomas. J NCCN 2011.
Making the students feel at ease in a large teaching hospital was the job of more than 75 MGH volunteers who hosted 100 students throughout the campus on Feb. 1 as part of the annual MGH Job Shadow Day, sponsored by the Center for Community Health Improvement.
55 Fruit Street
Boston MA, 02114-2696